You have read all your free articles, to continue reading subscribe to read the rest of this content.
Novo Nordisk has announced that the Japanese Ministry of Health, Labour and Welfare has approved Rybelsus (oral semaglutide), the first and only oral glucagon-like peptide-1 receptor agonist (GLP-1 RA) in a tablet, for the treatment of adults with type 2 diabetes. The approval of Rybelsus in JapaAlready a subscriber Login…
Sobi has announced that its contract with Pfizer for the manufacture of drug substance for ReFacto AF/Xyntha (ReFacto) has been amended due to clarity of final order volumes and will now expire in the first quarter of 2024, earlier than the previous expiry date at the end of 2025. Manufacturing…
Pharmaceutical company MSD is moving to the new Stockholm life science cluster. The company has been located in Sollentuna, outside of Stockholm, for the last 25 years but will change locations to Hagastaden during the spring of 2015. "For MSD in Sweden it is important to be part of the…
Inficure Bio has signed an agreement with a publicly listed US biopharmaceutical company that develops drugs for several chronic and life-threatening diseases. “We will now begin testing the effects of their drug substances in our model. The company is world-leading in drug development, so thisAlready a subscriber Login You have…
